Understanding why some breast cancers don't respond to treatment
Project 3: Characterization of the biology of non-responders using Imaging and molecular analysis to inform treatment
This project helps us learn more about why certain breast cancers don't respond well to standard treatments, using advanced imaging and molecular tests to guide future care.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California, San Francisco NIH-funded |
| Lab location | 1 site (San Francisco, United States) |
| Project ID | NIH-11125950 on NIH RePORTER |
What this research studies
This project is part of the I-SPY2.2 trial, a large effort to find better treatments for high-risk, early-stage breast cancer. We are looking closely at patients who don't fully respond to initial chemotherapy, using detailed imaging and molecular analysis of their tumors. Our goal is to understand the unique biology of these cancers so we can develop more personalized and effective treatment plans. This approach helps us quickly identify new drug combinations and tailor therapies based on how a patient's tumor responds.
Who could benefit from this research
Good fit: This research is relevant for patients with high-risk, early-stage breast cancer who are undergoing neoadjuvant chemotherapy.
Not a fit: Patients with other types or stages of cancer, or those not receiving neoadjuvant chemotherapy for breast cancer, may not directly benefit from this specific research.
Why it matters
Potential benefit: If successful, this work could lead to more effective, personalized treatments for breast cancer patients, especially those whose tumors are resistant to current therapies.
How similar studies have performed: The previous I-SPY2 trial successfully identified several new therapies that significantly improved patient outcomes and advanced to definitive Phase III trials.
Where this research is happening
San Francisco, United States
- University of California, San Francisco — San Francisco, United States (Active)
Researchers
- Principal investigator: Van't Veer, Laura J — University of California, San Francisco
- Study coordinator: Van't Veer, Laura J
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.